Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PALI

PALI - Palisade Bio, Inc. Stock Price, Fair Value and News

$1.69-0.12 (-6.63%)
Market Closed

80/100

PALI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

80/100

PALI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.86

Target 3M

$2.26

Target 6M

$2.58

PALI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PALI Price Action

Last 7 days

-3.4%

Last 30 days

-31.8%

Last 90 days

-12.9%

Trailing 12 Months

12.7%

PALI RSI Chart

PALI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PALI Valuation

Market Cap

251.8M

Price/Earnings (Trailing)

-22.43

Price/Sales (Trailing)

1.1K

Price/Free Cashflow

-24.97

PALI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.86

Target 3M

$2.26

Target 6M

$2.58

PALI Fundamentals

PALI Revenue

Revenue (TTM)

250.0K

PALI Earnings

Earnings (TTM)

-11.2M

Earnings Growth (Yr)

17.75%

Earnings Growth (Qtr)

-3.02%

PALI Profitability

Return on Equity

-349.5%

Return on Assets

-160.99%

Free Cashflow Yield

-4%

PALI Investor Care

Shares Dilution (1Y)

11107.33%

Diluted EPS (TTM)

-1.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023257.5K255.0K252.5K250.0K
202018.9K13.5K13.5K13.5K
2019198.8K137.7K76.5K15.4K
2018260.0K260.0K260.0K260.0K
201716.2K16.2K16.2K260.0K
201610.0K10.0K10.0K16.2K
201517.6K15.1K12.6K10.4K
201411.7K14.2K16.7K18.8K
2013354.0K278.3K110.0K110.0K
2012394.9K399.2K403.4K407.7K
201100562.0K390.6K
2010000733.4K
Get all data in R, Python etc through our Historical Stock Data APIs

About Palisade Bio, Inc.

PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.
 CEO
 WEBSITEpalisadebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Palisade Bio, Inc. Frequently Asked Questions

PALI is the stock ticker symbol of Palisade Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Palisade Bio, Inc. is 251.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PALI's fair value in chart for subscribers.

The fair value guage provides a quick view whether PALI is over valued or under valued. Whether Palisade Bio, Inc. is cheap or expensive depends on the assumptions which impact Palisade Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PALI.

As of Wed Jan 28 2026, PALI's PE ratio (Price to Earnings) is -22.43 and Price to Sales (PS) ratio is 1.05 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PALI PE ratio will change depending on the future growth rate expectations of investors.